# Emerging Role of Tau Citrullination During Alzheimer’s disease and Tauopathies

> **NIH NIH RF1** · UNIVERSITY OF KENTUCKY · 2021 · $1,672,789

## Abstract

Emerging Role of Tau Citrullination During Alzheimer’s disease and Tauopathies
Human tauopathies are a group of neurological disorders, including Alzheimer’s disease (AD), for which no
disease modifying therapies exist. Tau proteinopathic phenotypes show a spectrum of pathological hallmarks
and clinical syndromes. There is increasing recognition that post-translational modifications (PTMs) promote
strain or conformational assemblies that contribute to tauopathies, signifying a need to understand how novel
PTMs contribute to tauopathy risk. Protein citrullination (citR), induced by peptidyl arginine deiminases (PADs),
leads to an irreversible PTM that alters protein structure/ function by neutralizing positively charged arginine
residues within proteins. We discovered that aberrant tau activates PAD4 in neurons (protein PAD4, gene
PADi4); tau is client of PAD4 and is citrullinated at 14 arginine residues and those changes are associated with
reduced tau fibrillization; citR prevents tau phosphorylation of key epitopes and impacts tau clearance; and tau
citR is elevated in AD and in animal models of tauopathy. Our central hypothesis argues that increased PAD4-
induced tau citR prevents higher-order fibrillization, which decreases tangle formation, alters tau metabolism,
impacts structure/ function, and reduces seeding activity. Assumptions of this model will be tested in vivo and in
vitro by neuronal PADi4 overexpression and conditional knockout mice, multiple biochemical techniques,
electrophysiologic, and behavioral approaches. We will establish how neuronal PADi4 expression impacts tau
neuropathologic changes. Aim 1 will advance our understanding for PADi4 gain/ loss of function to establish the
foundation for citR tau biology and the impact on behavior in different models of tauopathy. We will establish
how citR regulates tau biochemistry and biology in cellular models. Aim 2 will mechanistically determine how
PAD4-induced citR tau alters tau clearance, aggregation, seeding and microtubule binding. We will establish the
spatio-temporal signature of citR tau in common human tauopathies. Aim 3 will provide the qualitative framework
and seeding activity of citR tau in common human tauopathies. The proposed work provides the necessary
foundation in not only better characterizing the role of citR in tauopathies, but also further establishing the first
mechanistic cause for loss and gain of function of PAD4 during tau pathogenesis. Overall, our application
describes a new tau PTM and provide a therapeutic strategy for a new pathway in tau biology and in AD.

## Key facts

- **NIH application ID:** 10231514
- **Project number:** 1RF1AG072728-01
- **Recipient organization:** UNIVERSITY OF KENTUCKY
- **Principal Investigator:** Daniel Carl Lee
- **Activity code:** RF1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,672,789
- **Award type:** 1
- **Project period:** 2021-05-01 → 2024-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10231514

## Citation

> US National Institutes of Health, RePORTER application 10231514, Emerging Role of Tau Citrullination During Alzheimer’s disease and Tauopathies (1RF1AG072728-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10231514. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*